Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T12:01:38.260Z.
Calculation as of: 2026-10-06T12:01:38.260Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f12fe6f09ebba39ad61e3a87243b01e46bba3d7bd48a90cbad4cda1dbeff8bd9
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$46.79M
EV/FCF Ratio
N/A
TTM Avg
16.14x
3Y Avg
18.58x
5Y Avg
128.19x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Clene Inc. (CLNN) | $49.96M | N/A | N/A | N/A | N/A |
| Envoy Medical, Inc. (COCH)vs › | $50.25M | N/A | N/A | N/A | N/A |
| Celularity Inc. (CELU)vs › | $49.50M | N/A | N/A | N/A | N/A |
| Apollomics, Inc. (APLM)vs › | $50.51M | N/A | N/A | N/A | N/A |
| biote Corp. (BTMD)vs › | $49.40M | 8.48x | 5.77x | 8.01x | 6.98x |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $51.12M | N/A | N/A | N/A | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $51.23M | N/A | N/A | N/A | N/A |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $52.95M | N/A | N/A | N/A | N/A |
| BioStem Technologies, Inc. (BSEM)vs › | $46.79M | N/A | 16.14x | 18.58x | 128.19x |
| Aldeyra The (ALDX)vs › | $55.72M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
